Monday September 28, 2020

Site-seeing in Rovaniemi

A ride from city centre to Santa Claus Village and back for only €20. Call us at +358 4510 26112 Email: riderovaniemi@gmail.com

6 coronavirus vaccine candidates now in phase-3 trials: WHO

Published : 07 Aug 2020, 00:30

  DF News Desk

Photo taken on July 21, 2020 shows a general view of the 125 London Wall building, where medical journal The Lancet's London office is based. A phase 2 trial of a COVID-19 vaccine candidate conducted in China has found that the vaccine is safe and induces an immune response, according to a new study published in medical journal The Lancet. File Photo Xinhua.

Six COVID-19 vaccine candidates, including three from China, have entered phase-3 trials, a senior World Health Organization (WHO) official said on Thursday, reported Xinhua.

The three Chinese candidates are from Sinovac, Wuhan Institute of Biological Products/Sinopharm and Beijing Institute of Biological Products/Sinopharm, said Michael Ryan, executive director of the WHO Health Emergencies Program, at a virtual briefing.

The other three are made by the University of Oxford/AstraZeneca, Moderna/NIAID and BioNTech/Fosun Pharma/Pfizer, he added.

The vaccines will be put into the general population for the first time in phase 3, after previous trials have focused on safety, immunogenicity and immune response in a small number of humans, said the WHO official. The phase-3 trial will test whether the vaccines can "protect large numbers of people over a prolonged period of time."

However, "phase-3 doesn't mean nearly there," he said, as "there is no guarantee that any of these six will give us the answer."

In total, 165 vaccine candidates have started some forms of trials, and 26 of them in clinical trials, according to WHO records.